Molecular Imaging

Molecular imaging (also called nuclear medicine or nuclear imaging) can image the function of cells inside the body at the molecular level. This includes the imaging modalities of positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. How does PET and SPECT imaging work? Small amounts of radioactive material (radiopharmaceuticals) injected into a patient. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

Thumbnail

FDG PET could forecast breast cancer patients’ response to therapy

Quantitative PET using agents like FDG could predict the outcome of chemotherapy for patients with particularly tricky cases of advanced breast cancer, according to a study published Dec. 4 in the Journal of Nuclear Medicine.

Thumbnail

NeuroLaunch aids ignition for neuscience startups

NeuroLaunch, the first major worldwide program for neuroscience technology businesses, is taking Atlanta by storm in a rolling 90-day program aimed to give participants and their companies the tools needed to succeed, including seed funding, mentorship, and other resources, such as access to top research centers.

Thumbnail

XTuit Pharmaceuticals brings in $4M investment for cancer research

A $4 million boon is going to Waltham, Mass.-based biomedical company XTuit Pharmaceuticals. The cancer therapy researchers behind XTuit plan to raise an additional $6 million in investments, according to a recent filing with the U.S. Securities and Exchange Commission.

Thumbnail

Theranostic PET could predict renal cancer progression after therapy

A novel PET technique combining a diagnostic radionuclide with a therapeutic agent can now map the potential results of therapy for advanced renal cell carcinoma, according to a study published Dec. 4 in the Journal of Nuclear Medicine. 

Thumbnail

Genomics market on the rise

The genomics market is expected to grow at an annual compound growth rate of 7.28 percent from 2013 to 2018, according to a recent market report from market research firms Infiniti Research Limited and TechNavio. 

BRIC diagnostic imaging markets to reach $7.6B by 2018

The diagnostic imaging markets in Brazil, Russia, India and China—known as the BRIC markets, are expected to grow at a compound annual growth rate of 10.5 percent, reaching $7.6 billion within the next four years.

Thumbnail

SPECT Alzheimer’s imaging gains more momentum

PET has dominated the amyloid imaging ring for several years now, but a preclinical study is showing some signs that SPECT could give PET a run for its money eventually, especially in translational research, according to a study published Dec. 4 in the Journal of Nuclear Medicine.

Thumbnail

Protein relays how patients will respond to cancer immunotherapy

A protein that suppresses immune response could tell researchers how patients taking a novel cancer immunotherapy will fare, Yale officials announced Nov. 26. The discovery could predict immune response in the treatment of a wide variety of cancers.